ECSP19043231A - Inhibidores de la tirosina quinasa de bruton - Google Patents
Inhibidores de la tirosina quinasa de brutonInfo
- Publication number
- ECSP19043231A ECSP19043231A ECSENADI201943231A ECDI201943231A ECSP19043231A EC SP19043231 A ECSP19043231 A EC SP19043231A EC SENADI201943231 A ECSENADI201943231 A EC SENADI201943231A EC DI201943231 A ECDI201943231 A EC DI201943231A EC SP19043231 A ECSP19043231 A EC SP19043231A
- Authority
- EC
- Ecuador
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- bruton tyrosine
- alkyl
- hal
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Un compuesto de la Fórmula I: V2 V1 N N R1 R6 R4 R11 LR 3 n k Fórmula I o un estereoisómero, solvato o sal farmacéuticamente aceptable de este, en donde: V1 es C o N, V2 es C(R2) o N, de manera que si V1 es С entonces V2 es N, si V1 es С entonces V2 es С(R2), o si V1 es N entonces V2 es С(R2); cada n, k es independientemente 0, 1; cada R2, R11 es independientemente H, D, Hal, CN, NR’R’’, C(O)NR’R’’, alcoxi C1-C6; R3 es H, D, hidroxi, alquilo С(O)C1-C6, alquenilo С(О)С2-С6, alquinilo С(О)С2-С6, alquilo C1-C6; R4 es H, Hal, CN, CONR’R’’, hidroxi, alquilo C1-C6, alcoxi C1-C6; L es CH2, NH, О o enlace químico; R1 se selecciona del grupo de fragmentos, que consiste en: A1 A2 A4 A3 N O R5 R5 Fragmento 1, A1 A2 A4 A3 O A9 A8 A7 A6 A5 R5 Fragmento 2,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424041P | 2016-11-18 | 2016-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19043231A true ECSP19043231A (es) | 2019-06-30 |
Family
ID=60574666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201943231A ECSP19043231A (es) | 2016-11-18 | 2019-06-17 | Inhibidores de la tirosina quinasa de bruton |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20190352276A1 (es) |
| EP (1) | EP3541811A1 (es) |
| JP (1) | JP2019537611A (es) |
| KR (1) | KR20190104516A (es) |
| CN (1) | CN110177781A (es) |
| AU (1) | AU2017362066A1 (es) |
| BR (1) | BR112019009945A2 (es) |
| CA (1) | CA3043297A1 (es) |
| CL (1) | CL2019001330A1 (es) |
| CR (1) | CR20190261A (es) |
| EA (1) | EA201990902A1 (es) |
| EC (1) | ECSP19043231A (es) |
| JO (1) | JOP20190113A1 (es) |
| MA (1) | MA45888A1 (es) |
| MX (1) | MX2019005706A (es) |
| PE (1) | PE20191082A1 (es) |
| PH (1) | PH12019550083A1 (es) |
| WO (1) | WO2018092047A1 (es) |
| ZA (1) | ZA201903694B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793566B2 (en) * | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102384924B1 (ko) * | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| WO2019013562A1 (ko) * | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| HUE065965T2 (hu) * | 2019-09-26 | 2024-06-28 | Jumbo Drug Bank Co Ltd | 4-fluor-1H-pyrazolo[3,4-C]piridin-származékok mint szelektív bruton-tirozinkináz (BTK) inhibitorok a B-sejtes limfóma és autoimmun betegségek kezelésére |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| US20230391779A1 (en) * | 2020-08-17 | 2023-12-07 | Betta Pharmaceuticals Co., Ltd. | Bicyclic compounds, compositions and use thereof |
| WO2022083741A1 (zh) * | 2020-10-23 | 2022-04-28 | 上海辉启生物医药科技有限公司 | 吡唑并吡啶类化合物或其盐及其制备方法和用途 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN116348453B (zh) * | 2021-04-25 | 2025-07-04 | 烨辉医药科技(上海)有限公司 | 杂芳族甲酰胺化合物及其用途 |
| WO2025202889A1 (en) * | 2024-03-28 | 2025-10-02 | Array Biopharma Inc. | Her2 mutation inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| EP2789615B1 (en) * | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| JP6348492B2 (ja) * | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物 |
| EP3082809B1 (en) * | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| BR112016016844A2 (pt) * | 2014-02-03 | 2017-08-08 | Cadila Healthcare Ltd | Compostos heterocíclicos |
| CN106999494A (zh) * | 2014-08-01 | 2017-08-01 | 药品循环有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| KR102699906B1 (ko) * | 2016-01-21 | 2024-08-29 | 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 | 브루톤 티로신 키나제 억제제 |
| JP6972002B2 (ja) * | 2016-03-11 | 2021-11-24 | エンジェル・ファーマシューティカル・カンパニー・リミテッド | ブルトン型チロシンキナーゼを調節する化合物及び方法 |
-
2017
- 2017-06-16 JO JOP/2019/0113A patent/JOP20190113A1/ar unknown
- 2017-11-16 MX MX2019005706A patent/MX2019005706A/es unknown
- 2017-11-16 CA CA3043297A patent/CA3043297A1/en not_active Abandoned
- 2017-11-16 US US16/461,537 patent/US20190352276A1/en not_active Abandoned
- 2017-11-16 JP JP2019525970A patent/JP2019537611A/ja active Pending
- 2017-11-16 WO PCT/IB2017/057154 patent/WO2018092047A1/en not_active Ceased
- 2017-11-16 KR KR1020197016234A patent/KR20190104516A/ko not_active Withdrawn
- 2017-11-16 AU AU2017362066A patent/AU2017362066A1/en not_active Abandoned
- 2017-11-16 PE PE2019001009A patent/PE20191082A1/es unknown
- 2017-11-16 BR BR112019009945A patent/BR112019009945A2/pt not_active Application Discontinuation
- 2017-11-16 EP EP17809035.3A patent/EP3541811A1/en not_active Withdrawn
- 2017-11-16 CR CR20190261A patent/CR20190261A/es unknown
- 2017-11-16 CN CN201780081869.5A patent/CN110177781A/zh active Pending
- 2017-11-16 MA MA45888A patent/MA45888A1/fr unknown
-
2019
- 2019-05-07 EA EA201990902A patent/EA201990902A1/ru unknown
- 2019-05-10 PH PH12019550083A patent/PH12019550083A1/en unknown
- 2019-05-16 CL CL2019001330A patent/CL2019001330A1/es unknown
- 2019-06-10 ZA ZA2019/03694A patent/ZA201903694B/en unknown
- 2019-06-17 EC ECSENADI201943231A patent/ECSP19043231A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110177781A (zh) | 2019-08-27 |
| CR20190261A (es) | 2019-09-02 |
| PE20191082A1 (es) | 2019-08-20 |
| JP2019537611A (ja) | 2019-12-26 |
| CL2019001330A1 (es) | 2019-09-27 |
| CA3043297A1 (en) | 2018-05-24 |
| JOP20190113A1 (ar) | 2019-05-15 |
| WO2018092047A1 (en) | 2018-05-24 |
| US20190352276A1 (en) | 2019-11-21 |
| KR20190104516A (ko) | 2019-09-10 |
| ZA201903694B (en) | 2021-04-28 |
| AU2017362066A1 (en) | 2019-05-30 |
| MA45888A1 (fr) | 2020-06-30 |
| MX2019005706A (es) | 2019-07-08 |
| PH12019550083A1 (en) | 2020-03-09 |
| EP3541811A1 (en) | 2019-09-25 |
| BR112019009945A2 (pt) | 2019-08-13 |
| EA201990902A1 (ru) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19043231A (es) | Inhibidores de la tirosina quinasa de bruton | |
| ECSP24026637A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| CL2020000427A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| EA202192029A1 (ru) | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| EA202192019A1 (ru) | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения | |
| PH12021500014A1 (en) | Fused ring compounds | |
| MX2024008118A (es) | Compuestos de anillo fusionado. | |
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| CR20220234A (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
| AR109348A1 (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| AR108711A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| JP2016532715A5 (es) | ||
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| PH12020552261A1 (en) | Proteasome activity enhancing compounds | |
| NZ779146A (en) | Cyclic molecules as bruton’s tyrosine kinase inhibitor | |
| MX2016010411A (es) | Compuestos agonistas de gpr142. | |
| ZA202507396B (en) | Fused ring compounds | |
| WO2017191657A9 (en) | Glycolactam compounds, process for preparation and uses thereof |